Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 85

1.

External financial aid to blood transfusion services in sub-Saharan Africa: a need for reflection.

Ala F, Allain JP, Bates I, Boukef K, Boulton F, Brandful J, Dax EM, El Ekiaby M, Farrugia A, Gorlin J, Hassall O, Lee H, Loua A, Maitland K, Mbanya D, Mukhtar Z, Murphy W, Opare-Sem O, Owusu-Ofori S, Reesink H, Roberts D, Torres O, Totoe G, Ullum H, Wendel S.

PLoS Med. 2012;9(9):e1001309. doi: 10.1371/journal.pmed.1001309. Epub 2012 Sep 11.

2.

Nonoccupational post-exposure prophylaxis source tracing: is it really feasible in Australia?

Pierce AB, Armishaw J, Price B, Wright EJ, Dax EM, Fairley CK, Hoy JF.

HIV Med. 2012 Aug;13(7):436-8. doi: 10.1111/j.1468-1293.2011.00986.x. Epub 2012 Jan 25.

3.

Assessment of the heat stability of seven rapid HIV assays.

Learmonth KM, Chiu CY, Galang H, Nawang MJ, Dax EM.

Trans R Soc Trop Med Hyg. 2011 Jul;105(7):388-95. doi: 10.1016/j.trstmh.2011.04.005. Epub 2011 May 28.

PMID:
21621232
4.

Photographed rapid HIV test results pilot novel quality assessment and training schemes.

Chiu YH, Ong J, Walker S, Kumalawati J, Gartinah T, McPhee DA, Dax EM.

PLoS One. 2011 Mar 31;6(3):e18294. doi: 10.1371/journal.pone.0018294.

5.

High viral fitness during acute HIV-1 infection.

Arnott A, Jardine D, Wilson K, Gorry PR, Merlin K, Grey P, Law MG, Dax EM, Kelleher AD, Smith DE, McPhee DA; Pulse Study Team.

PLoS One. 2010 Sep 9;5(9). pii: e12631. doi: 10.1371/journal.pone.0012631.

6.

Immunoassays for the diagnosis of HIV: meeting future needs by enhancing the quality of testing.

Chappel RJ, Wilson KM, Dax EM.

Future Microbiol. 2009 Oct;4(8):963-82. doi: 10.2217/fmb.09.77. Review.

PMID:
19824789
7.

An international quality control programme for PRISM chemiluminescent immunoassays in blood service and blood product laboratories.

Walker S, Dimech W, Kiely P, Smeh K, Francis B, Karakaltsas M, Dax EM.

Vox Sang. 2009 Nov;97(4):309-16. doi: 10.1111/j.1423-0410.2009.01218.x. Epub 2009 Aug 4.

PMID:
19682349
8.

TREAT Asia Quality Assessment Scheme (TAQAS) to standardize the outcome of HIV genotypic resistance testing in a group of Asian laboratories.

Land S, Cunningham P, Zhou J, Frost K, Katzenstein D, Kantor R, Chen YM, Oka S, DeLong A, Sayer D, Smith J, Dax EM, Law M; TAQAS Laboratory Network.

J Virol Methods. 2009 Aug;159(2):185-93. doi: 10.1016/j.jviromet.2009.03.016. Epub 2009 Mar 26.

9.

Transfusion medicine and safety.

Dodd R, Kurt Roth W, Ashford P, Dax EM, Vyas G.

Biologicals. 2009 Apr;37(2):62-70. doi: 10.1016/j.biologicals.2009.01.006. Epub 2009 Feb 20. Review.

PMID:
19230706
10.

Evaluation of eight anti-rubella virus immunoglobulin g immunoassays that report results in international units per milliliter.

Dimech W, Panagiotopoulos L, Francis B, Laven N, Marler J, Dickeson D, Panayotou T, Wilson K, Wootten R, Dax EM.

J Clin Microbiol. 2008 Jun;46(6):1955-60. doi: 10.1128/JCM.00231-08. Epub 2008 Apr 23.

11.

Assessing proficiency of interpretation of rapid human immunodeficiency virus assays in nonlaboratory settings: ensuring quality of testing.

Learmonth KM, McPhee DA, Jardine DK, Walker SK, Aye TT, Dax EM.

J Clin Microbiol. 2008 May;46(5):1692-7. doi: 10.1128/JCM.01761-07. Epub 2008 Mar 19.

12.

Advances in quality assurance of laboratory testing for transfusion safety.

Dax EM, Walker S.

Dev Biol (Basel). 2007;127:183-95. No abstract available.

PMID:
17486892
13.

HIV testing in 2006: issues and methods.

Chang D, Learmonth K, Dax EM.

Expert Rev Anti Infect Ther. 2006 Aug;4(4):565-82. Review.

PMID:
17009937
14.

Humoral immune response to primary rubella virus infection.

Wilson KM, Di Camillo C, Doughty L, Dax EM.

Clin Vaccine Immunol. 2006 Mar;13(3):380-6.

15.

Commercial enzyme immunoassay adapted for the detection of antibodies to hepatitis C virus in dried blood spots.

Croom HA, Richards KM, Best SJ, Francis BH, Johnson EI, Dax EM, Wilson KM.

J Clin Virol. 2006 May;36(1):68-71. Epub 2006 Jan 19.

PMID:
16426889
16.

Evaluation of three immunoassays used for detection of anti-rubella virus immunoglobulin M antibodies.

Dimech W, Panagiotopoulos L, Marler J, Laven N, Leeson S, Dax EM.

Clin Diagn Lab Immunol. 2005 Sep;12(9):1104-8.

17.

Advances in laboratory testing for HIV.

Dax EM, Arnott A.

Pathology. 2004 Dec;36(6):551-60. Review.

PMID:
15841690
18.

Incidence immunoassay for distinguishing recent from established HIV-1 infection in therapy-naive populations.

Wilson KM, Johnson EI, Croom HA, Richards KM, Doughty L, Cunningham PH, Kemp BE, Branson BM, Dax EM.

AIDS. 2004 Nov 19;18(17):2253-9.

PMID:
15577537
19.

Validation of assembled nucleic acid-based tests in diagnostic microbiology laboratories.

Dimech W, Bowden DS, Brestovac B, Byron K, James G, Jardine D, Sloots T, Dax EM.

Pathology. 2004 Feb;36(1):45-50. Review.

PMID:
14757556
20.

New precision in measuring trachoma infection.

Taylor HR, Dax EM.

Lancet. 2003 Jul 19;362(9379):181-2. No abstract available.

PMID:
12885474
21.

Quality assessment program for genotypic antiretroviral testing improves detection of drug resistance mutations.

Sayer DC, Land S, Gizzarelli L, French M, Hales G, Emery S, Christiansen FT, Dax EM.

J Clin Microbiol. 2003 Jan;41(1):227-36.

22.

External quality assessment program for Chlamydia trachomatis diagnostic testing by nucleic acid amplification assays.

Land S, Tabrizi S, Gust A, Johnson E, Garland S, Dax EM.

J Clin Microbiol. 2002 Aug;40(8):2893-6.

23.

Sensitivity of HCV RNA and HIV RNA blood screening assays.

Lelie PN, van Drimmelen HA, Cuypers HT, Best SJ, Stramer SL, Hyland C, Allain JP, Moncharmont P, Defer C, Nübling M, Glauser A, da Silva Cardoso M, Viret JF, Lankinen MH, Grillner L, Wirthmüller U, Coste J, Schottstedt V, Masecar B, Dax EM.

Transfusion. 2002 May;42(5):527-36.

PMID:
12084160
24.

Variant Creutzfeldt-Jakob disease in Australian blood donors: estimation of risk and the impact of deferral strategies.

Correll PK, Law MG, Seed CR, Gust A, Buring M, Dax EM, Keller AJ, Kaldor JM.

Vox Sang. 2001 Jul;81(1):6-11.

PMID:
11520409
25.

Quality of human immunodeficiency virus viral load testing in Australia.

Best SJ, Gust AP, Johnson EI, McGavin CH, Dax EM.

J Clin Microbiol. 2000 Nov;38(11):4015-20.

27.

Blood screening--the next generation in testing.

Chappel RJ, Dax EM.

Aust N Z J Med. 1999 Dec;29(6):763-4. No abstract available.

PMID:
10677118
28.

Serological testing algorithms for the diagnosis of HIV infection.

Dax EM.

AIDS. 1999 Jan 14;13(1):133-4. No abstract available.

PMID:
10207555
29.

Assays for HIV with improved sensitivity and specificity.

Best SJ, Dax EM.

Expert Opin Investig Drugs. 1997 Aug;6(8):965-83.

PMID:
15989656
30.

If it's the virus why aren't we measuring it?

Dax EM, Best SJ.

Med J Aust. 1996 Jul 15;165(2):119. No abstract available.

PMID:
8692058
31.

Multisite evaluation of four anti-HIV-1/HIV-2 enzyme immunoassays. Australian HIV Test Evaluation Group.

Silvester C, Healey DS, Cunningham P, Dax EM.

J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Apr 1;8(4):411-9.

PMID:
7882108
32.

False-negative results for HIV-1.

Anderson JS, Locarnini SA, Doherty RR, Breschkin AM, Dax EM, Mijch AM.

Med J Aust. 1995 Feb 20;162(4):220. No abstract available.

PMID:
7877548
33.

A comparison of the performance of nine commercially available anti-HTLV-I screening assays.

Karopoulos A, Silvester C, Dax EM.

J Virol Methods. 1993 Nov;45(1):83-91.

PMID:
8270658
34.

HTLV-I associated myelopathy in a Seychellois immigrant.

Thyagarajan D, Bastian I, Stark RJ, Day BJ, Dax EM, Gilligan BS.

Med J Aust. 1993 Jul 5;159(1):29-31.

PMID:
8316110
35.

Beta adrenergic regulation of rat liver glycogenolysis during aging.

Katz MS, Dax EM, Gregerman RI.

Exp Gerontol. 1993 Jul-Oct;28(4-5):329-40. Review.

PMID:
8224032
36.

Occupational exposure to the human immunodeficiency virus and other blood-borne pathogens. A six-year prospective study.

Bowden FJ, Pollett B, Birrell F, Dax EM.

Med J Aust. 1993 Jun 21;158(12):810-2.

PMID:
8326890
37.

HIV antibody testing in Australia.

Dax EM, Vandenbelt TA.

J Acquir Immune Defic Syndr. 1993;6 Suppl 1:S24-8. Review.

PMID:
8426298
38.

Identification of infection of an Australian resident with the human immunodeficiency virus type 2 (HIV-2).

Downie JC, Dwyer DE, Kazazi F, Chew CB, Dowton DN, Randle C, Singh V, Dax EM, Cunningham AL.

Med J Aust. 1992 Sep 21;157(6):415-7.

PMID:
1447996
39.

An evaluation of two simple synthetic peptide based anti-HIV assays.

Healey DS, Dax EM.

J Virol Methods. 1992 Aug-Sep;38(3):305-12.

PMID:
1430054
40.

Low risk of HIV-1 infection from blood donation: a test-based estimate.

Dax EM, Healey DS, Crofts N.

Med J Aust. 1992 Jul 6;157(1):69-70. No abstract available.

PMID:
1640903
41.
43.

Chronic cocaine administration and withdrawal of cocaine modify neurotensin binding in rat brain.

Pilotte NS, Mitchell WM, Sharpe LG, De Souza EB, Dax EM.

Synapse. 1991 Oct;9(2):111-20.

PMID:
1821482
44.

Followup study of possible HIV seropositivity among abusers of parenteral drugs in 1971-72.

Lange WR, Ball JC, Adler WH, Brown E, Pyle R, Hoffman W, Dax EM.

Public Health Rep. 1991 Jul-Aug;106(4):451-5.

45.

Acute marijuana smoking reduces vagal tone.

Newlin DB, Pretorius MB, Wong CJ, Dax EM.

NIDA Res Monogr. 1990;105:565-6. No abstract available.

PMID:
1876121
46.

Changes in mood, craving and sleep during acute abstinence reported by male cocaine addicts.

Weddington WW, Brown BS, Cone EJ, Haertzen CA, Dax EM, Herning RI, Michaelson BS.

NIDA Res Monogr. 1990;105:453-4. No abstract available.

PMID:
1876074
47.

Amyl nitrite alters human in vitro immune function.

Dax EM, Adler WH, Nagel JE, Lange WR, Jaffe JH.

Immunopharmacol Immunotoxicol. 1991;13(4):577-87.

PMID:
1685501
48.

Short-term D9-tetrahydrocannabinol (THC) does not affect neuroendocrine or immune parameters.

Dax EM, Pilotte NS, Adler WH, Nagel JE, Lange WR.

NIDA Res Monogr. 1990;105:567-8. No abstract available.

PMID:
1652093
49.

Chronic cocaine administration and withdrawal from cocaine modify central neurotensin receptors in rats.

Pilotte NS, Mitchell WM, Sharpe LG, De Souza E, Dax EM.

NIDA Res Monogr. 1990;105:541-2. No abstract available.

PMID:
1652092
50.

Supplemental Content

Support Center